title: Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.
abstract: Many therapies are now available for patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate including tumor necrosis factor inhibitors, abatacept, tocilizumab, and rituximab. Clinical response to drugs varies widely between individuals. A part of this variability is due to the characteristics of the patient such as age, gender, concomitant therapies, body mass index, or smoking status. Clinical response also depends on disease characteristics including disease activity and severity and presence of autoantibodies. Genetic background, cytokine levels, and immune cell phenotypes could also influence biological therapy response. This review summarizes the impact of all those parameters on response to biological therapies.
authors: Department of Rheumatology, Lapeyronie Hospital, University Montpellier I-II and IGMM-UMR5535, CNRS 1919, Route de Mende, 34295 Montpellier Cedex 5, France.
authors: Claire I
authors: CI
authors: Daïen
authors: Department of Rheumatology, Lapeyronie Hospital, University Montpellier I-II and IGMM-UMR5535, CNRS 1919, Route de Mende, 34295 Montpellier Cedex 5, France.
authors: Jacques
authors: J
authors: Morel
mesh_terms: D000069594:Abatacept; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics; D001688:Biological Products / Q000627:therapeutic use; D015992:Body Mass Index; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000737:chemistry; D010641:Phenotype; D057285:Precision Medicine / Q000379:methods*; D012074:Remission Induction; D000069283:Rituximab; D012737:Sex Factors; D012907:Smoking; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001688:Biological Products; D016207:Cytokines; D018796:Immunoconjugates; D000069283:Rituximab; D000069594:Abatacept; C502936:tocilizumab; D008727:Methotrexate